Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro and in vivo studies show enhanced...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Goldenberg, David M., Cardillo, Thomas M., Govindan, Serengulam V., Rossi, Edmund A., Sharkey, Robert M.
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2015
主題:
Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4673178/
https://ncbi.nlm.nih.gov/pubmed/26101915
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍